Status:
COMPLETED
Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus
Lead Sponsor:
Ain Shams University
Conditions:
Non Alcoholic Fatty Liver Disease
Eligibility:
All Genders
Brief Summary
This study included 70 subjects divided into 3 groups. Group I included 25 patients with NAFLD. Group II included 25 patients with NAFLD and chronic HCV. Group III: included 20 controls. Abdominal ult...
Eligibility Criteria
Inclusion
- Patients with NAFLD.
- Patients with NAFLD and chronic hepatitis C viral infection.
Exclusion
- Current or past consumption of significant amount of alcohol more than 21 drinks and 14 drinks per week for men and women respectively.
- Patients receiving Drugs which cause fatty liver as amiodarone, diliazem, tamoxifen, steroids.
- Patients who take statins as it has lowering effect on plasma PTX3.
- Patients having any clinical evidence of hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding, elevated serum bilirubin level to more than two folds the upper limit of normal.
- Patients with heart failure.
- Patients with autoimmune rheumatic disease.
- Patients with chronic kidney diseases.
- Patients with sepsis.
Key Trial Info
Start Date :
April 15 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2016
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03276039
Start Date
April 15 2014
End Date
July 30 2016
Last Update
September 8 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.